Table 2.
Cycle threshold (CT) values of SARS-CoV-2 PCR of 11 COVID-19 patients treated with remdesivir
| First initial SARS-CoV-2 test | PCR CT value 1 | PCR CT value 2 | PCR CT value 3 | |
|---|---|---|---|---|
| Patient 1 | PCR positive | 17.07 | 23.69 | 32.63 |
| Days since start remdesivir | − 33 | 0 | 4 | 14 |
| Specimen | NP | NP | NP | NP |
| Patient 2 | No prior test | 26.17 | 21.81 | |
| Days since start remdesivir | − 4 | 3 | ||
| Specimen | NP | NP | ||
| Patient 3 | Antigen positive | 24.26 | 20.46 | 31.15 |
| Days since start remdesivir | − 27 | − 2 | − 1 | 3 |
| Specimen | NP | BAL | NP | |
| Patient 4 | PCR positive | 35.66 | ||
| Days since start remdesivir | − 15 | 0 | ||
| Specimen | NP | NP | ||
| Patient 5 | PCR positive | 28.49 | 33.34 | |
| Days since start remdesivir | − 44 | − 3 | 3 | |
| Specimen | NP | S | S | |
| Patient 6 | PCR positive | 20.71 | ||
| Days since start remdesivir | − 87 | − 1 | ||
| Specimen | BAL | BAL | ||
| Patient 7 | PCR positive | 17.57 | 24.62 | 31.43 |
| Days since start remdesivir | − 12 | 0 | 8 | 13 |
| Specimen | NP | S | S | NP |
| Patient 8 | Antigen positive | 26.21 | 29.91* | |
| Days since start remdesivir | − 46 | − 6 | 3 | |
| Specimen | BAL | S | ||
| Patient 9 | PCR positive | 28.31 | ||
| Days since start remdesivir | − 59 | − 1 | ||
| Specimen | NP | NP | ||
| Patient 10 | PCR positive | 22.96 | 27.09 | 28.18 |
| Days since start remdesivir | − 47 | − 3 | 3 | 9 |
| Specimen | NP | NP | NP | NP |
| Patient 11 | No prior test | 25.23* | ||
| Days since start remdesivir | 31 | |||
| Specimen | BAL |
CT values prior to start or at beginning of remdesivir in bold type (median 24.6). CT values obtained during or within 5 days after treatment marked in italic type (median 29.7). Day of first dose of remdesivir defined as day 0
CT cycle threshold of the E-gene, NP nasopharyngeal swab, BAL bronchoalveolar lavage, S sputum
*N-gene amplification